OCT 16, 2018 10:00 PM PDT

Potential Targeted Treatment for Crohn Disease

WRITTEN BY: Nouran Amin

Emerging as a global disease with rates increasing the past 5 decades, Crohn’s disease (CD) is the chronic inflammation of the intestinal tract.

Now, recent research at Cornell University and University of North Carolina (UNC) is a step closer to advancing drug treatments for CD patients. Such research proposes the potential targeting of a key molecule, called microRNA-31 (miR-31), which can predict if a patient has subtype 1 or subtype 2 of Crohn’s disease. This is particularly crucial because patients with subtype 1, unlike subtype 2, will often not respond to treatments which can lead to the surgical interventions for strictures – the extreme narrowing of the gut. With clinical markers like miR-31, healthcare providers may be able to better asses a CD patient if they should consider pre-emptive surgery before the condition worsens.

“We are not at the point at which we are able to perform personalized medicine on this, but at the very least we think it can lead to better clinical trial designs,” says Praveen Sethupathy, senior co-author of the study.

Previously, clinical trials assessing a new drug for CD has grouped all patients together causing inconsistent results. However, using miR-31, scientists are now able to separate individuals with CD into subtypes for better drug assessment. The results of the study published in the journal JCI Insight.

Credit: Drug Target Review

“Our study hints that it’s not only that miR-31 could be a predictive indicator of clinical outcome, but also that it could be functionally relevant in driving the disease,” explains Sethupathy.

Researchers are now hopeful for future studies that will determine the exact role of miR-31 in gut biology. “Our long-term goal, extending the work of this study, is to better understand at the molecular level why CD is so different in its presentation across patients, and to use this knowledge to develop more effective therapies,” says Terrence Furey, an associate professor of genetics.

Source: Drug Target Review

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUL 13, 2018
Drug Discovery
JUL 13, 2018
Pharmacological Strategy Attempts To Treat Multiple Symptoms of Fragile X
Recent research in a mouse model of fragile X syndrome (FXS), scheduled for publication in Neuropsychopharmacology, shows that a pharmacological strategy c...
AUG 08, 2018
Drug Discovery
AUG 08, 2018
Cholesterol Pill For Treating A Brutal Lung Disease
A brutal lung disease called Pulmonary Alveolar Proteinosis (PAP) is caused by a thick substance known as surfactant that clogs up the air sacs in the lung...
SEP 02, 2018
Genetics & Genomics
SEP 02, 2018
Insights From the Opium Poppy Genome
By sequencing the opium poppy's DNA, scientists have revealed important details about how it makes its medicine....
SEP 18, 2018
Drug Discovery
SEP 18, 2018
More Challenges in Immunotherapeutic Developments
Fighting disease using the immune system is the body’s most prized possession and it does so by utilizing immunotherapy. However, a discovery by rese...
SEP 18, 2018
Drug Discovery
SEP 18, 2018
Clinical-Grade Drugs for Bone Diseases
According to a study published in Journal of Gerontology: Biological Sciences, a small molecule was discovered to play a role in bone formation, ultimately...
NOV 05, 2018
Drug Discovery
NOV 05, 2018
Anti-Parasitic Drug Improves Long-term Clinical Outcomes in Chagas Disease
In a recent study published in PLOS Neglected Tropical Diseases, an anti-parasite drug by the name of ‘benznidazole’ may hold potential in impr...
Loading Comments...